{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T16:14:55Z","timestamp":1768407295235,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is an extensive and growing body of knowledge regarding disease-modifying treatment (DMT) in multiple sclerosis (MS) regarding their effects, impact on functioning and potential side-effects. Few studies have, however, investigated the patients\u2019 perspectives regarding their experiences of DMT in daily life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To investigate and describe the experience of DMT in the daily lives of patients with MS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A qualitative design was applied using semi-structured interviews with eight patients with MS on different types of DMT. The interviews were analyzed using qualitative content analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three themes emerged from the analysis; Fulfilled expectations in the light of previous treatments, Continuous need for treatment and side effect management, and Need for personalized feedback from the MS care team.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The patients\u2019 described experiences and hopes for personalized treatment plans, procedures, and feedback on DMT outcome implicate the need for further development of person-centred interventions. Development of such care interventions should consider the patients\u2019 perspectives on e.g., treatment preferences and procedures, social support, and the professionalism and expert-knowledge of MS care team professionals. The knowledge derived from this study may also inform the development of patient-reported experience- and outcome measures regarding daily life with DMT in MS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-025-04576-9","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T06:03:49Z","timestamp":1765346629000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Experiences of disease-modifying treatments in patients with multiple sclerosis \u2013 a qualitative study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9050-4584","authenticated-orcid":false,"given":"Kristina","family":"Gottberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7896-7682","authenticated-orcid":false,"given":"Marie","family":"Kierkegaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-5938","authenticated-orcid":false,"given":"Birgitta Jakobsson","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3704-8887","authenticated-orcid":false,"given":"Charlotte","family":"Ytterberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"4576_CR1","volume-title":"McAlpine\u2019s multiple sclerosis","year":"2006","unstructured":"McAlpine D, Compston A, Confavreux C, Lassmann H, McDonald I, Miller D, Noseworthy J, Smith K, Wekerle H, editors. McAlpine\u2019s multiple sclerosis. 4 ed. Philadelphia, Pa.: Churchill Livingstone\/Elsevier; 2006.","edition":"4"},{"issue":"1","key":"4576_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","volume":"4","author":"M Filippi","year":"2018","unstructured":"Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4(1):43.","journal-title":"Nat Rev Dis Primers"},{"key":"4576_CR3","unstructured":"Swedish Medical Products Agency. L\u00e4kemedelsverket. 2023. www.lakemedelsverket.se. Accessed 15 Dec 2023."},{"key":"4576_CR4","unstructured":"National Board of Health and Welfare. National guidelines. Nationella riktlinjer - indikatorer f\u00f6r v\u00e5rd vid multipel skleros och parkinsons sjukdom. 2023. www.socialstyrelsen.se. Accessed 15 Dec 2023."},{"issue":"8","key":"4576_CR5","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S1474-4422(22)00209-5","volume":"21","author":"A Svenningsson","year":"2022","unstructured":"Svenningsson A, Frisell T, Burman J, Salzer J, Fink K, Hallberg S, et al. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurol. 2022;21(8):693\u2013703.","journal-title":"Lancet Neurol"},{"key":"4576_CR6","unstructured":"The Swedish MS-Association. 2023.\u00a0https:\/\/www.mssallskapet.se. Accessed 15 Dec 2023."},{"issue":"3","key":"4576_CR7","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1600-0404.2009.01285.x","volume":"121","author":"A Cunningham","year":"2010","unstructured":"Cunningham A, Gottberg K, von Koch L, Hillert J. Non-adherence to interferon-beta therapy in Swedish patients with multiple sclerosis. Acta Neurol Scand. 2010;121(3):154\u201360.","journal-title":"Acta Neurol Scand"},{"issue":"7","key":"4576_CR8","doi-asserted-by":"publisher","first-page":"e0133279","DOI":"10.1371\/journal.pone.0133279","volume":"10","author":"K Hansen","year":"2015","unstructured":"Hansen K, Sch\u00fcssel K, Kieble M, Werning J, Schulz M, Friis R, et al. Adherence to disease modifying drugs among patients with multiple sclerosis in germany: A retrospective cohort study. PLoS One. 2015;10(7):e0133279.","journal-title":"PLoS One"},{"issue":"1 Suppl A","key":"4576_CR9","first-page":"S24","volume":"19","author":"J Menzin","year":"2013","unstructured":"Menzin J, Caon C, Nichols C, White LA, Friedman M, Pill MW. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm. 2013;19(1 Suppl A):S24\u201340.","journal-title":"J Manag Care Pharm"},{"key":"4576_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104461","volume":"69","author":"K Daniels","year":"2023","unstructured":"Daniels K, Frequin STFM, van de Garde EMW, Biesma DH, van der Wees PJ, van der Nat PB, et al. Development of an international, multidisciplinary, patient-centered Standard Outcome Set for Multiple Sclerosis: the S.O.S.MS project. Mult Scler Relat Disord. 2023;69:104461.","journal-title":"Mult Scler Relat Disord"},{"key":"4576_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103475","volume":"58","author":"K Westergaard","year":"2022","unstructured":"Westergaard K, Skovgaard L, Magyari M, Kristiansen M. Patient perspectives on patient-reported outcomes in multiple sclerosis treatment trajectories: a qualitative study of why, what, and how? Mult Scler Relat Disord. 2022;58:103475.","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"4576_CR12","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1177\/1352458516657441","volume":"23","author":"P Vermersch","year":"2017","unstructured":"Vermersch P, Hobart J, Dive-Pouletty C, Bozzi S, Hass S, Coyle PK. Measuring treatment satisfaction in MS: is the treatment satisfaction questionnaire for medication fit for purpose? Mult Scler. 2017;23(4):604\u201313.","journal-title":"Mult Scler"},{"issue":"9","key":"4576_CR13","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1177\/1352458516676643","volume":"23","author":"P de Flon","year":"2017","unstructured":"de Flon P, Laurell K, S\u00f6derstr\u00f6m L, Gunnarsson M, Svenningsson A. Improved treatment satisfaction after switching therapy to rituximab in relapsing-remitting MS. Mult Scler. 2017;23(9):1249\u201357.","journal-title":"Mult Scler"},{"issue":"5","key":"4576_CR14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1177\/135245850000600510","volume":"6","author":"K Gottberg","year":"2000","unstructured":"Gottberg K, Gardulf A, Fredrikson S. Interferon-beta treatment for patients with multiple sclerosis: the patients\u2019 perceptions of the side-effects. Mult Scler. 2000;6(5):349\u201354.","journal-title":"Mult Scler"},{"issue":"1","key":"4576_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/00002820-200401000-00007","volume":"27","author":"J Larsen","year":"2004","unstructured":"Larsen J, Nordstr\u00f6m G, Ljungman P, Gardulf A. Symptom occurrence, symptom intensity, and symptom distress in patients undergoing high-dose chemotherapy with stem-cell transplantation. Cancer Nurs. 2004;27(1):55\u201364.","journal-title":"Cancer Nurs"},{"issue":"1","key":"4576_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/01376517-200602000-00008","volume":"38","author":"CE Miller","year":"2006","unstructured":"Miller CE, Jezewski MA. Relapsing MS patients\u2019 experiences with glatiramer acetate treatment: a phenomenological study. J Neurosci Nurs. 2006;38(1):37\u201341.","journal-title":"J Neurosci Nurs"},{"issue":"1","key":"4576_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.7224\/1537-2073-14.1.39","volume":"14","author":"CE Miller","year":"2012","unstructured":"Miller CE, Karpinski M, Jezewski MA. Relapsing-remitting multiple sclerosis patients\u2019 experience with natalizumab: a phenomenological investigation. Int J MS Care. 2012;14(1):39\u201344.","journal-title":"Int J MS Care"},{"issue":"1","key":"4576_CR18","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1186\/s12913-021-07012-z","volume":"21","author":"A Sippel","year":"2021","unstructured":"Sippel A, Riemann-Lorenz K, Scheiderbauer J, Kleiter I, Morrison R, Kofahl C, et al. Patients experiences with multiple sclerosis disease-modifying therapies in daily life - a qualitative interview study. BMC Health Serv Res. 2021;21(1):1141.","journal-title":"BMC Health Serv Res"},{"issue":"7","key":"4576_CR19","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1007\/s12325-022-02164-8","volume":"39","author":"M Gudesblatt","year":"2022","unstructured":"Gudesblatt M, Roman C, Singer BA, Schmidt H, Thomas J, Shankar SL, et al. Health-related quality of life with diroximel fumarate in patients with relapsing forms of multiple sclerosis: findings from qualitative research using patient interviews. Adv Ther. 2022;39(7):3199\u2013213.","journal-title":"Adv Ther"},{"issue":"4","key":"4576_CR20","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.dhjo.2019.05.005","volume":"12","author":"A Buesa-Estell\u00e9z","year":"2019","unstructured":"Buesa-Estell\u00e9z A, Cano-de-la-Cuerda R, Ortiz-Guti\u00e9rrez RM, Palacios-Ce\u00f1a D. The impact of pharmacological treatment on patients with multiple sclerosis. Disabil Health J. 2019;12(4):615\u201321.","journal-title":"Disabil Health J"},{"key":"4576_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103464","volume":"58","author":"G Carey","year":"2022","unstructured":"Carey G, Wilson N, Janssen J, Chohan A, Rog D, Roddam H. I\u2019m walking into the unknown\": qualitative insights into how emotions and lived experience related to multiple sclerosis diagnosis impact on decisions to pursue disease modifying treatment. Multiple Sclerosis and Related Disorders. 2022;58:103464.","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"8","key":"4576_CR22","doi-asserted-by":"publisher","first-page":"e0182806","DOI":"10.1371\/journal.pone.0182806","volume":"12","author":"A van Ceuninck","year":"2017","unstructured":"van Ceuninck A, Meide HV, Vosman FJH, Visser LH. A qualitative study assessing patient perspectives in the process of decision-making on disease modifying therapies (DMT\u2019s) in multiple sclerosis (MS). PLoS One. 2017;12(8):e0182806.","journal-title":"PLoS One"},{"issue":"8","key":"4576_CR23","doi-asserted-by":"publisher","first-page":"e037701","DOI":"10.1136\/bmjopen-2020-037701","volume":"10","author":"JL Larsen","year":"2020","unstructured":"Larsen JL, Sch\u00e4fer J, Nielsen HH, Vestergaard Rasmussen P. Qualitative factors shaping MS patients\u2019 experiences of infusible disease-modifying drugs: a critical incident technique analysis. BMJ Open. 2020;10(8):e037701.","journal-title":"BMJ Open"},{"issue":"2","key":"4576_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.nedt.2003.10.001","volume":"24","author":"UH Graneheim","year":"2004","unstructured":"Graneheim UH, Lundman B. Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. Nurse Educ Today. 2004;24(2):105\u201312.","journal-title":"Nurse Educ Today"},{"key":"4576_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2020.103632","volume":"108","author":"BM Lindgren","year":"2020","unstructured":"Lindgren BM, Lundman B, Graneheim UH. Abstraction and interpretation during the qualitative content analysis process. Int J Nurs Stud. 2020;108:103632.","journal-title":"Int J Nurs Stud"},{"issue":"7","key":"4576_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.3104","volume":"13","author":"S Persson","year":"2023","unstructured":"Persson S, Andersson AC, G\u00e4re BA, Lindenfalk B, Lind J. Lived experience of persons with multiple sclerosis: a qualitative interview study. Brain Behav. 2023;13(7):e3104.","journal-title":"Brain Behav"},{"issue":"9","key":"4576_CR27","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1177\/1049732310371103","volume":"20","author":"M Olsson","year":"2010","unstructured":"Olsson M, Sk\u00e4r L, S\u00f6derberg S. Meanings of feeling well for women with multiple sclerosis. Qual Health Res. 2010;20(9):1254\u201361.","journal-title":"Qual Health Res"},{"issue":"7","key":"4576_CR28","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1177\/1352458508089688","volume":"14","author":"K Gottberg","year":"2008","unstructured":"Gottberg K, Einarsson U, Ytterberg C, Fredrikson S, von Koch L, Holmqvist LW. Use of health care services and satisfaction with care in people with multiple sclerosis in Stockholm county: a population-based study. Mult Scler. 2008;14(7):962\u201371.","journal-title":"Mult Scler"},{"issue":"5","key":"4576_CR29","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1080\/09638288.2022.2046187","volume":"45","author":"G Topcu","year":"2023","unstructured":"Topcu G, Mhizha-Murira JR, Griffiths H, Bale C, Drummond A, Fitzsimmons D, et al. Experiences of receiving a diagnosis of multiple sclerosis: a meta-synthesis of qualitative studies. Disabil Rehabil. 2023;45(5):772\u201383.","journal-title":"Disabil Rehabil"},{"issue":"1","key":"4576_CR30","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1186\/s12913-020-05278-3","volume":"20","author":"A Bourdin","year":"2020","unstructured":"Bourdin A, Dubois J, Foley RA, Schluep M, Bugnon O, Berger J. Satisfaction and experiences of patients taking Fingolimod and involved in a pharmacy-based patient support program in Switzerland - a qualitative study. BMC Health Serv Res. 2020;20(1):425.","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"4576_CR31","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/ane.13453","volume":"144","author":"AM Landtblom","year":"2021","unstructured":"Landtblom AM, Berntsson SG, Bostr\u00f6m I, Iacobaeus E. Multiple sclerosis and COVID-19: the Swedish experience. Acta Neurol Scand. 2021;144(3):229\u201335.","journal-title":"Acta Neurol Scand"},{"issue":"5","key":"4576_CR32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1136\/qshc.2005.016527","volume":"15","author":"P Bate","year":"2006","unstructured":"Bate P, Robert G. Experience-based design: from redesigning the system around the patient to co-designing services with the patient. Qual Saf Health Care. 2006;15(5):307\u201310.","journal-title":"Qual Saf Health Care"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04576-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04576-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04576-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T10:05:46Z","timestamp":1768385146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-025-04576-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4576"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04576-9","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Regional Ethical Review Board in Stockholm (from 2019: The Swedish Ethical Review Authority) approved the study (2017\/937\u2009\u2212\u200931) in line with the Ethics Review Act (legislation number 2003:460). Informed consent was obtained from all participants. All methods were carried out in accordance with the Helsinki declaration. The patients were informed both orally and in written form about their right to withdraw at any time without the need for giving a reason. No illiterate patients were involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The participants were informed that participation in the study meant publication of the results in a scientific paper, including non-identifiable background data on e.g., age, sex, and pharmacological treatment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}